Australian National Clinical Evidence Taskforce COVID-19 drug treatment guidelines: challenges of producing a living guideline
Abstract
The National Clinical Evidence Taskforce (NCET) established coronavirus disease 2019 (COVID-19) drug treatment guidelines in March 2020 to provide clinicians with living evidence-based recommendations for the care of patients with COVID-19. These guidelines have been widely used and have informed practice in Australia and beyond. However, there are limitations to the available evidence, and, as the COVID-19 pandemic has progressed, the NCET has had to address a number of challenges. This perspective article discusses these limitations and challenges and the strategies developed to ensure that the guidelines remain relevant and useful for clinicians
Read the full publication here:
https://onlinelibrary.wiley.com/doi/10.5694/mja2.52044
Authors:
Bridget E Barber, Heath White, Alexis P Poole, Joshua S Davis, Steven A McGloughlin, Tari Turner